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Quercetin is an important dietary flavonoid with putative beneficial effects in the prevention of cancer and CVD. The in vivo bioactivity of
quercetin depends on its bioavailability, which varies widely between foods. We used an in situ rat intestinal perfusion model to study
whether differential small intestinal hydrolysis of the sugar moiety of five naturally occurring quercetin glycosides determines the
small intestinal uptake and subsequent biliary excretion of quercetin. After 30 min perfusion, a decrease of intact quercetin glycoside
in perfusate was observed for quercetin-3-O-ß-glucoside (20·9 (SEM 1·4) mmol/l) and quercetin-40-O-ß-glucoside (23·5 (SEM 1·6) mmol/
l), but not of quercetin-3-O-ß-galactoside, quercetin-3-O-ß-rhamnoside and quercetin-3-O-a-arabinopyranoside. Appearance of free quer-
cetin in perfusate and conjugated quercetin metabolites (quercetin, isorhamnetin, and tamarixetin) in portal and peripheral plasma and bile
were also significantly greater after treatment with quercetin-3-O-ß-glucoside or quercetin-40-O-ß-glucoside compared with any of the
other glycosides. Thus, the type of sugar moiety is a major determinant of the small intestinal absorption of quercetin glycosides, but
the position (3 or 40) of the glucose moiety does not further influence absorption. The poor bioavailability of important dietary quercetin
glycosides has implications for their in vivo bioactivities.
Flavonoid: Quercetin glycoside: Intestinal absorption: Lactase phlorizin hydrolase: Bile
Quercetin is an important dietary flavonoid with antioxi-
dant, anti-inflammatory, antiproliferative and anticarcino-
genic properties (Nijveldt et al. 2001). Because of its
putative beneficial effects in the prevention of cancer and
CVD, quercetin is used as a food supplement and a prom-
ising ingredient of so-called functional foods (Verhoeyen
et al. 2002). The in vivo bioactivity of quercetin is deter-
mined by concentrations at target sites, and thus by the
degree of intestinal absorption from the diet, by metab-
olism, and by excretion into bile, urine and faeces, i.e. its
bioavailability. The bioavailability of quercetin from
different foods varies widely (Hollman et al. 1997), and
it is unclear what causes this. In plant foods, quercetin
occurs almost exclusively bound to one or more sugar
molecules, so-called quercetin-b-glycosides. The dominant
type of glycoside varies between foods. Apple, for
example, contains predominantly galactosides, rhamno-
sides and arabinosides, while onion contains mainly gluco-
sides (Hollman & Arts, 2000). We hypothesise that the
sugar moiety is an important determinant of the bioavail-
ability of quercetin from foods. There is some evidence
in the literature to support this hypothesis: while querce-
tin-3-glucoside and quercetin-40-glucoside were rapidly
absorbed in human subjects, quercetin-3-rutinoside
(a diglycoside predominant in tea) was not (Hollman
et al. 1997; Olthof et al. 2000).
Because b-glycosides are resistant to hydrolysis by pan-
creatic enzymes, absorption of quercetin-b-glycosides was
at first thought to occur only after hydrolytic enzymes from
the colonic microflora had released the aglycone. However,
Hollman et al. (1997) showed that quercetin appeared in
plasma only 30 min after ingestion of quercetin gluco-
side-rich foods, pointing at absorption in the small intes-
tine. At first, the mechanisms involved in small intestinal
uptake and transport of intact quercetin glycosides were
thought to be mediated by Na-dependent glucose trans-
porter 1, followed by cytosolic ß-glucosidase-mediated
hydrolysis of the sugar moiety (Hollman et al. 1999;
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Day & Williamson, 2001). Although these pathways may
contribute to the absorption of quercetin glycosides, it is
becoming increasingly clear that lactase phlorizin hydro-
lase (LPH) is the main determinant of uptake (Day et al.
2003; Sesink et al. 2003). LPH is a mammalian b-glycosi-
dase present in the brush border membrane of the small
intestine; it is thought to play a role in the rapid in vivo
uptake of these quercetin glucosides (Day et al. 2000b).
In vitro studies with purified LPH from lamb intestine
showed that several flavonoid glucosides were indeed
substrates for this enzyme (Day et al. 2000b). We
recently demonstrated that during perfusion of the rat
small intestine with quercetin-3-glucoside, inhibition of
LPH caused a 67 % reduction in quercetin-3-glucoside
hydrolysis, concomitant with a 75 % reduction in plasma
quercetin concentration (Sesink et al. 2003). The sub-
strate-specificity of LPH for hydrolysis of different querce-
tin glycosides may vary and thus contribute to their varying
bioavailability.
Upon absorption, the biological activity of quercetin can
be modified by conjugation reactions, such as glucuronida-
tion and/or sulfation, which take place in the cells of the
intestine and liver (Rice-Evans et al. 1996; Day et al.
2000a). In addition, hydroxyl groups of the catechol-ring
can be methylated by the enzyme catechol-O-methyltrans-
ferase. The main O-methylated derivative of quercetin in
plasma of human subjects and rats is isorhamnetin (querce-
tin-30-methyl ether; Hollman & Arts, 2000; Stahl et al.
2002). Bile is considered an important excretion route for
flavonoids. However, firm evidence to support this conten-
tion is limited, and it is unclear whether the excretion pat-
tern differs between quercetin glycosides. In rats that were
fed a high-quercetin diet for 14 d, the concentration of
quercetin in bile was sevenfold higher than that in
plasma, and an additional metabolite, tamarixetin (querce-
tin-40-methyl ether), was detected (Manach et al. 1998).
Thus far, the small intestinal uptake of different querce-
tin glycosides and their subsequent biliary excretion as
conjugated metabolites has not been systematically investi-
gated. In the present study, we used an in situ rat intestinal
perfusion model to study whether the appearance of quer-
cetin and its methylated derivatives in plasma and bile is
determined by small intestinal hydrolysis of five major
quercetin monoglycosides (40-glucoside, 3-glucoside,
3-galactoside, 3-rhamnoside and 3-arabinoside).
Materials and methods
Chemicals
Quercetin-3-O-ß-glucoside (Q3glucoside), quercetin-40-O-
ß-glucoside (Q40glucoside), quercetin-3-O-ß-galactoside
(Q3galactoside), quercetin-3-O-ß-rhamnoside (Q3rhamno-
side), quercetin-3-O-a-arabinopyranoside (Q3arabinoside)
and tamarixetin (quercetin-40-methyl ether) were purchased
from Extrasynthese (Genay, France). The identity of
Q3arabinoside was confirmed using nuclear magnetic
resonance because it was previously sold wrongly
labelled as quercetin-3-O-a-arabinofuranoside (avicularin;
Lommen et al. 2000). Isorhamnetin (quercetin-30-methyl
ether) was purchased from Roth (Karlsruhe, Germany).
Quercetin and ß-glucuronidase–sulfatase (Helix pomatia,
G1512) were obtained from Sigma (St Louis, MO, USA).
All other chemicals used were of analytical grade. A mix
of quercetin glucuronides used in the present study was
kindly provided by Karen O’Leary (Institute of Food
Research, Norwich, Norfolk, UK).
Animals and diets
The experimental protocol was approved by the Animal
Welfare Committee of Wageningen University, Wagenin-
gen, The Netherlands. Male outbred Wistar rats (Harlan,
Horst, The Netherlands; specific pathogen free, n 31),
mean body weight 208 (SD 8·1) g, were housed individu-
ally in a room with controlled temperature (22–248C)
and relative humidity (50–60 %) and a 12 h light–dark
cycle (lights on 06.00 hours). For three consecutive days
before the experiment, all rats were fed a commercially
available soyabean-free semipurified diet (composition
(g/kg): dextrose 540, cellulose 50, maize starch 100,
casein 200, maize oil 50, standard AIN-76 vitamin and
mineral mix 5; Hope Farms, Woerden, The Netherlands).
After 3 d plasma quercetin levels in all rats were below
the limit of detection (11 nmol/l).
In situ perfusion studies
After limiting the feed intake overnight to 5 g, rats were
anaesthetised by inhalation of isoflurane, using NO–O2
(1:1, v/v) as carrier. First, the abdominal cavity was
opened and the bile duct and portal vein were cannulated.
Then two cannulas (internal diameter 1·52 mm) were
inserted in the small intestine (duodenum, jejunum and
ileum), distal of the entrance of the bile duct in the duode-
num and proximal of the caecum. The contents of the can-
nulated segment were removed before inserting the most
distal cannula by flushing gently with 60 ml saline (9 g
NaCl/l, 378C). Perfusion was started by injecting 10 ml
test solution (378C) into the cannulated segment and con-
necting the intestine immediately to a single-pass perfusion
system. Constant perfusion took place at a flow rate of
1 ml/min at 378C, using a potassium phosphate buffer
(5 mM, pH 6·7) containing (mmol/l): NaCl 100, KCl 20,
CaCl2 2, MgCl2 2, sodium taurocholate 0·5.
The perfusion buffer was supplemented with 50mmol
Q3glucoside, Q40glucoside, Q3galactoside, Q3rhamnoside
or Q3arabinoside/l. In control experiments where these
glycosides were incubated in perfusion fluid at 378C for
60 min, there was no disappearance of the glycosides and
no free aglycone formed, indicating that they were stable
under the experimental conditions. Perfusion was stopped
after 30 min, and in the last minute 1 ml samples were
taken from the perfusion fluid at the end of the cannulated
segment and at the inlet of the perfused segment (for the t
0 min sample). In a pilot experiment where the small intes-
tine was perfused for 60 min with Q3glucoside, steady-
state plasma and perfusion buffer concentrations were
reached at t 30 min (results not shown). Effluent samples
were stabilised with acetic acid (10 mM, pH 4·9) and
ascorbic acid (1 g/l, final concentrations). Volume changes
in perfusion buffer during perfusion were recorded
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by weighing. Perfusion buffer volumes recovered
did not differ significantly between groups (one-way
ANOVA, P¼0·97) and were 33·2 (Q3glucoside), 32·8
(Q40glucoside), 34·4 (Q3galactoside), 33·5 (Q3rhamnoside)
and 33·3 (Q3arabinoside). Because volume changes were
due not only to water absorption during intestinal passage,
but also to sampling, some spilling, and injecting approxi-
mately 10 ml into the intestine before starting perfusion,
these data could not be used to correct effluent sample con-
centrations of the glycosides. Because hydrolysis and
absorption of Q3rhamnoside was almost negligible (indi-
cated by the absence of free quercetin and quercetin metab-
olites in perfusion fluid and plasma), the 6 % increase in
perfusion buffer concentration of Q3rhamnoside during
intestinal passage was attributed to water absorption.
Thus, all t 30 perfusion buffer data presented here have
been reduced by 6 %. Bile was collected in two portions
(from 0–15 and from 15–30 min). Before the experiment,
and at 15 and 30 min, blood was drawn from the cannu-
lated portal vein, and after the experiment peripheral
blood was drawn from the inferior vena cava. Blood was
collected in EDTA-tubes and plasma was subsequently
prepared by centrifuging for 10 min at 2000 g and 48C.
All samples were stored at 2808C before analysis.
Preparation of samples
Samples were analysed using a validated HPLC-coularray
method (Arts et al. 2003). In plasma and bile, quercetin
and its methylated metabolites isorhamnetin and
tamarixetin only occur as glucuronidated and/or sulfated
conjugates, so enzymatic hydrolysis with ß-glucuroni-
dase–sulfatase is required. In the remainder of the present
paper, when referring to quercetin, isorhamnetin or tamar-
ixetin concentrations in plasma or bile, the total concen-
tration after hydrolysis of the conjugates is meant.
Perfusion buffer effluents were only analysed without
previous treatment with ß-glucuronidase–sulfatase.
Plasma (50ml) was incubated with 0·25 mg b-glucuroni-
dase–sulfatase (Helix pomatia, 125 U b-glucuronidase
and 7 U sulfatase) in 20ml 0·5 M-sodium acetate buffer
(pH 4·9) with 6 g ascorbic acid/l. After incubating for 2 h
at 378C, samples were deproteinised with 2 vols aceto-
nitrile and thoroughly mixed. Then, 1 vol. o-phosphoric
acid (200 ml/l, containing 3 g ascorbic acid/l) was added.
Samples were centrifuged for 10 min at 10 000 g and 48C
and analysed with HPLC. The analysis of bile was similar
to that of plasma: 35ml bile was incubated with 0·25 mg
b-glucuronidase–sulfatase in 15ml 0·5 M-sodium acetate
buffer (pH 4·9) with 6 g ascorbic acid/l. After incubation
for 1 h at 378C, samples were deproteinised with 2 vols
acetonitrile and 1 vol. o-phosphoric acid (200 ml/l). All
analyses were performed in simplo (single).
HPLC analysis
Merck Hitachi L6000A and L6200 pumps (Hitachi Ltd,
Tokyo, Japan) were equipped with a Gilson 234 autosam-
pler (Gilson, Villiers-le-Bel, France) and a coulometric
detector (Coularray detector model 5600; ESA, Chelms-
ford, MA, USA) set at 100, 250, and 500 mV (Pd as
reference). Separation of a 20ml sample was performed
on a Chromolith RP-18e column (100·0 £ 4·6 mm;
Merck, Darmstadt, Germany) protected by a NewGuard
RP18 guard column (15·0 £ 3·2 mm, 7mm; Perkin Elmer,
Norwalk, CT, USA). The columns were maintained at
308C with an ESA column heater. The solvents for gradient
elution were 50 ml acetonitrile/l (solvent A) and 700 ml
acetonitrile/l (solvent B) in citrate buffer (25 mM, pH
3·7). The following gradient, at a flow rate of 2·5 ml/min,
was used: 0·0–12·0 min, linear gradient from 0 to 43 %
B; 12·0–13·0 min, linear gradient to 100 % B; 13·0–
14·5 min, 100 % B; 14·5–15·5 min, linear gradient to 0 %
B. Total run time including equilibration was 17 min.
Statistical analyses
Results are presented as mean values with their standard
errors. One-way ANOVA followed by Bonferroni multiple
comparison tests were used to test for statistically signifi-
cant differences between treatment groups using the
SPSS statistical package (SPSS for Windows, version
10.0.5; SPSS Inc., Chicago, IL, USA). The area under
the concentration–time curve (AUC) for quercetin and iso-
rhamnetin in portal vein plasma was calculated by the
trapezoidal rule.
Results
After perfusing the rat small intestine for 30 min with
solutions of 50mmol Q3glucoside, Q40glucoside, Q3galac-
toside, Q3rhamnoside or Q3arabinoside/l, effluent concen-
trations of the intact glycoside were lower than
concentrations at the inlet for the Q3glucoside and the
Q40glucoside groups only (Fig. 1). The decline in concen-
tration was similar for Q3glucoside (20·9 (SEM 1·4) mmol/l)
and for Q40glucoside (23·5 (SEM 1·6) mmol/l), but both dif-
fered significantly from changes observed in the other
groups (P,0·05). At the same time, free quercetin
appeared in the effluent of the Q3glucoside (2·9 (SEM
0·5) mmol/l) and at a slightly higher concentration in the
Q40glucoside (6·1 (SEM 1·0) mmol/l) group (P,0·05), but
only marginally in the other groups (Fig. 1).
Fig. 2 shows that during perfusion, there was an increase
in portal vein plasma concentration of total quercetin (after
enzymatic hydrolysis of the glucuronide and sulfate conju-
gates) from 0 (limit of detection 11 nmol/l) to about
4mmol/l at 15 min and about 5mmol/l at 30 min in all
animals of the Q3glucoside and the Q40glucoside groups
(Fig. 2(A)). The AUC for these groups were similar (90·2
(SEM 9·0) and 101·3 (SEM 16·6) mmol·min/l respectively),
but differed significantly (P,0·05) from the other exper-
imental groups where only trace amounts of quercetin
were detected (up to 0·6 (SEM 0·1) mmol/l for Q3galacto-
side). A similar pattern was seen for the 30-methylated
quercetin metabolite isorhamnetin (Fig 2(B)). No isorham-
netin (limit of detection 14 nmol/l) could be detected in
plasma of the Q3galactoside, Q3rhamnoside and Q3arabi-
noside animals. Peripheral plasma was collected at
30 min only. Quercetin and isorhamnetin concentrations
in peripheral plasma were of the same order of magnitude
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as the portal vein concentrations at 30 min for all five
experimental groups (Table 1).
After absorption, quercetin metabolites were rapidly
excreted into the bile. In addition to quercetin and
isorhamnetin that were found in plasma, bile contained a
second methylated metabolite: tamarixetin. Quercetin, iso-
rhamnetin and tamarixetin were present in approximately
equimolar concentrations in bile (Fig. 3); this did not
vary between the first and second 15 min of sample collec-
tion (results not shown). In the sample obtained during the
first 15 min of perfusion, the total concentration of querce-
tin metabolites was 49·6 (SEM 20·6) mmol/l for the Q3glu-
coside and 34·0 (SEM 11·0) mmol/l for the Q40glucoside
group. Concentrations for the other experimental groups
did not exceed 5mmol/l (results not shown). During the
second 15 min, concentrations measured were as great as
324·1 (SEM 64·7) (Q3glucoside) and 349·3 (SEM 47·2)
mmol/l (Q40glucoside) (Fig. 3). The highest concentration
of metabolites in the other three experimental groups was
found after perfusion with Q3galactoside and amounted
to 16·3 (SEM 2·4) mM. Again, all individual metabolites
and the total metabolite concentrations were similar for
the Q3glucoside and Q40glucoside group, but differed
significantly from the other three groups (P,0·05).
Fig. 2. Portal vein plasma concentrations of total quercetin (A) (limit
of detection 11 nmol/l) and isorhamnetin (B) (limit of detection 14
nmol/l) measured by HPLC after enzymatic hydrolysis during in situ
perfusion of rat small intestine with 50mmol quercetin-3-O-ß-gluco-
side (W), quercetin-40-O-ß-glucoside (X), quercetin-3-O-ß-galacto-
side (K), quercetin-3-O-ß-rhamnoside (O) or quercetin-3-O-a-
arabinopyranoside (A)/l. For details of procedures, see p. 843.
Values are means with their standard errors shown by vertical bars
(n 6; n 7 for quercetin-3-O-ß-glucoside).
Table 1. Peripheral plasma concentrations (mmol/l) at t ¼ 30 min of
quercetin metabolites after enzymatic hydrolysis†
Quercetin Isorhamnetin Total
Mean SEM Mean SEM Mean SEM
Q3glucoside 3·8* 0·56 1·2* 0·19 5·0* 0·73
Q40glucoside 4·5* 0·83 1·1* 0·20 5·6* 1·01
Q3galactoside 0·5 0·10 0·0 0·02 0·6 0·12
Q3rhamnoside 0·0 0·02 ,LOD‡ - 0·0 0·02
Q3arabinoside 0·3 0·03 ,LOD‡ - 0·3 0·03
Q3glucoside, querceitin-3-O-ß-glucoside; Q40glucoside, quercetin-40-O-ß-glu-
coside; Q3galactoside, quercetin-3-O-ß-galactoside; Q3rhamnoside;
quercitin-3-O-ß-rhamnoside; Q3arabinoside, quercetin-3-O-a-arabinopyra-
noside; LOD, limit of detection.
*Mean values were significantly different from those of other quercetin glyco-
side groups: P,0·05.
† For details of procedures, see p. 843.
‡ LOD 14 nM.
Fig. 1. Change in concentration of quercetin glycosides (B) and quercetin aglycone (A) in perfusion buffer between 0 and 30 min in situ
perfusion of rat small intestine with 50mmol quercetin glycosides/l. Q3glucoside, quercetin-3-O-ß-glucoside; Q40glucoside, quercetin-40-O-ß-
glucoside; Q3galactoside, quercetin-3-O-ß-galactoside; Q3rhamnoside, quercetin-3-O-b-rhamnoside; Q3arabinoside, quercetin-3-O-a-arabino-
pyranoside. For details of procedures, see p. 843. Values are means with their standard errors shown by vertical bars (n 6; n 7 for Q3gluco-
side). a,b,cMean values with unlike superscript letters (above x-axis for quercetin aglycone and below x-axis for quercetin glycosides) were
significantly different between groups (P,0·05).
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Discussion
The results of the present study suggest that the type of
sugar, but not the position at which it is attached to the
quercetin molecule, is the major determinant of the small
intestinal absorption of quercetin in rats. Both Q3glucoside
and Q40glucoside were hydrolysed by b-glycosidases
present in the small intestine and were rapidly absorbed.
After perfusing the small intestine for 30 min with a
50mmol glucoside/l, peripheral plasma metabolite concen-
trations were as great as 5·0mmol/l for the 3-glucoside and
5·6mmol/l for the 40-glucoside. Portal vein plasma concen-
trations were slightly higher. In contrast, other glycosides
were resistant to intestinal hydrolysis and only trace
amounts of the metabolites of Q3galactoside, Q3rhamno-
side or Q3arabinoside were detected in plasma. The data
for perfusion buffer were in accordance with the plasma
findings, which supports data suggesting that intestinal
hydrolysis of the sugar moiety is a necessary step for
absorption of quercetin glycosides to occur (Crespy et al.
2001; Day et al. 2003; Sesink et al. 2003).
The rapid and efficient uptake of Q3glucoside and
Q40glucoside has been reported before for human subjects
(Olthof et al. 2000; Graefe et al. 2001), intact rats (Morand
et al. 2000) and isolated or in situ perfused small intestine
of rats (Spencer et al. 1999; Gee et al. 2000; Crespy et al.
2001; Day et al. 2003; Sesink et al. 2003). The absorption
of Q3glucoside and Q40glucoside have been compared in
only three studies. Olthof et al. (2000) found that the phar-
macokinetic profiles in human plasma were almost identi-
cal after ingestion of a single dose of either one of the
glucosides. This is an indication that our in situ perfusion
model is an appropriate model to study the small intestinal
uptake of quercetin glucosides in human subjects. In
accordance with our present study, both Gee et al. (2000)
and Day et al. (2003) found that after incubation of an
isolated rat intestinal segment with Q3glucoside and
Q40glucoside, serosal transfer and tissue concentrations of
quercetin and its metabolites were similar for both gluco-
sides. However, in their everted jejunal sac model mucosal
hydrolysis of Q40glucoside (represented as the appearance
of free quercetin in the mucosal solution) was reported to
be 10 times greater than Q3glucoside hydrolysis. In our
present study, mucosal quercetin aglycone concentration
was two times higher for Q40glucoside than for Q3gluco-
side, while hydrolysis of Q40glucoside (calculated as the
decrease in glucoside concentration before and after per-
fusion) was only 5 % greater than Q3glucoside hydrolysis.
Thus, only the direct measurement of glucosides, but not
the appearance of free quercetin, accurately reflects intesti-
nal hydrolysis of flavonoid glucosides.
Quercetin is predominantly found glycosylated at the
3- or 40-position, but a sugar can also be attached at
other positions in the parent molecule, such as the 7-
hydroxyl group. Because no pure quercetin-7-glucoside
could be obtained, we could not determine whether
uptake is influenced by conjugation at this position. The
limited data available for other flavonoids, however, do
not suggest that the small intestinal uptake of a 7-glucoside
would be much lower than the uptake of the aglycone, or
the corresponding 3- or 40-glucosides (Spencer et al.
1999; Felgines et al. 2000; Zubik & Meydani, 2003). In
addition, the substrate specificity of purified sheep LPH
was no different for luteolin 7- or 40-glucoside, and
hydrolysis of 7-glucosides of naringenin, eriodictyol and
apigenin occurred at rates similar to those reported for
Q3glucoside and Q40glucoside (Ne´meth et al. 2003).
In intact rats fed a single meal containing 66mmol
Q3glucoside or Q3rhamnoside, plasma levels of quercetin
metabolites were 33·2mmol/l for the Q3glucoside group
and not detectable for the Q3rhamnoside group at 4 h
after the start of the meal (Morand et al. 2000). This is
in line with our present findings. The intestinal absorption
of Q3galactoside and Q3arabinoside has, to our knowl-
edge, not been studied before. However, the substrate
specificity of purified sheep LPH for several flavonoid
Fig. 3. Bile concentrations of quercetin (B), isorhamnetin (B) and tamarixetin (A) measured by HPLC after enzymatic hydrolysis in the t 15–
30 min samples collected during in situ perfusion of rat small intestine with 50mmol quercetin glycoside/l. Values are means with their standard
errors shown by vertical bars (n 6; n 7 for quercetin-3-O-ß-glucoside). For details of procedures, see p. 843. a,bMean values with unlike super-
script letters were significantly different between groups for total and individual metabolite concentrations (P,0·05).
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glycosides has recently been published (Ne´meth et al.
2003). These fully support our present data: Q3glucoside
and Q40glucoside are good substrates for LPH with
hydrolysis rates of 3·16 and 3·08mmol/min per mg protein
respectively. Q3galactoside is a poor substrate (hydrolysis
rate 0·13), and Q3rhamnoside and Q3arabinoside were
not hydrolysed at all. This underlines the importance of
LPH in the small intestinal uptake of flavonoid glycosides.
Because LPH is traditionally considered a galactosidase, it
was rather surprising to find that Q3galactoside was
absorbed only to a very small extent, and that indeed
these data are supported by the low hydrolysis rate recently
reported by Ne´meth et al. (2003). The only difference
between Q3glucoside and Q3galactoside is the spatial
configuration of the hydroxyl group at the C4 position of
the sugar. This hydroxyl group seems to be a major deter-
minant of the hydrolysis rate.
In intact mammals, digestion is facilitated by the
secretion of enzymes in saliva and pancreatic juice. In
the small intestinal perfusion model, the quercetin glyco-
sides administered are not exposed to digestive juices,
which can potentially limit the generalisability of results
obtained with this model. The mammalian salivary
glands and pancreas do not contain a ß-glycosidase, but
they do secrete a-amylase, an enzyme that catalyses the
hydrolysis of a-D-glucosidic linkages (Wong & Robertson,
2003). Although Q3arabinoside is an a-glycoside, it is
unlikely that a-amylase will hydrolyse the sugar because
it has an L- and not a D-configuration. Thus, it is unlikely
that in intact rats the Q3arabinoside would be absorbed in
the small intestine.
Bile is generally considered an important excretion route
for flavonoids. However, firm evidence to support this
contention was thus far limited to one study. In line with
our findings, Manach et al. (1996) reported high equimolar
concentrations of quercetin, isorhamnetin and tamarixetin
in the bile of rats fed quercetin (2·5 g/kg diet) for 14 d.
The fact that both we and Manach et al. (1996) found no
tamarixetin in plasma suggests that this metabolite is not
formed in the intestine, but only in the liver and immedi-
ately excreted into bile. The high methylated:unmethylated
quercetin derivative ratio in bile (approximately 2·0) com-
pared with plasma (0·2) suggests that methylation of quer-
cetin strongly favours biliary excretion. Extremely efficient
clearance of tamarixetin from plasma is therefore an
alternative explanation. However, this is not likely to
explain the complete absence of tamarixetin from portal
vein plasma. Interestingly, in the study of Manach et al.
(1996) bile concentrations of quercetin metabolites were
similar to those in our present study, but plasma levels
were much greater. In their 14 d study with extremely
high doses of quercetin, adaptive mechanisms in intestinal
or hepatic metabolism and transport, or in the large intes-
tinal microflora, may have occurred; these did not take
place in our present short-term study. Once absorption of
the quercetin glycosides has taken place, metabolite pattern
and excretion rate into bile is no longer dependent on the
type of glycoside administered.
Thus, our present data are supportive of previous data
showing that hydrolysis of the sugar moiety is a necessary
step for absorption of quercetin glycosides in the small
intestine to occur. Of several glycosides tested in our pre-
sent study, only the 3-glucoside and the 40-glucoside were
absorbed in substantial quantities. The position of the
glucose moiety (3 or 40) did not influence absorption.
Excretion patterns into bile were similar for quercetin
glycosides with similar absorption characteristics.
Although it is commonly stated that glucose is the sugar
most frequently found in flavonol glycosides, two of the
three major sources of flavonols in the Netherlands, tea
and apple (Hertog et al. 1993), contain only small amounts
of flavonol glucosides. In apple, the major quercetin glyco-
sides are the galactoside, rhamnoside, arabinoside and
xyloside, with only 100 g glucoside/kg quercetin glyco-
sides. In tea the glucoside concentration is somewhat
greater, but still only 250 g/kg quercetin glycosides (Holl-
man & Arts, 2000). Our present data show that the bioa-
vailability of important dietary quercetin glycosides is
very poor. This has implications for the in vivo bioactivity
that can be expected after oral intake of these compounds.
Findings from the present study underline the importance
of compiling food composition tables with individual gly-
cosides rather than aglycones only, and are relevant for
manufacturers and consumers considering the production
and use of quercetin-enriched functional foods or
supplements.
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